---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036855"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:23:58.391668+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA

## Summary
- Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.
- Underwriters granted 45-day option for additional 232,500 shares at same price.
- Proceeds to fund Phase 1 lung cancer and Phase 2 prostate cancer trials for lead candidate ENV 105.
- Issued two warrants to underwriters for 54,250 shares each at $4.80 exercise price, exercisable from Mar 2025 to Sep 2029.
- Common stock began trading on NYSE American on Sept 16, 2024 under symbol KAPA.

## SEC filing metadata
- accession: 0001493152-24-036855
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/0001493152-24-036855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036855
- JSON: https://secwatch.observer/filing/0001493152-24-036855.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.